LENZ Therapeutics
LENZ
113 hedge funds and large institutions have $725M invested in LENZ Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 15 reducing their positions, and 16 closing their positions.
3,662% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $305K
253% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 15
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
34% more capital invested
Capital invested by funds: $542M → $725M (+$183M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11.34% more ownership
Funds ownership: 76.52% → 87.85% (+11%)
8% more funds holding
Funds holding: 105 → 113 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.9M |
| 2 |
Morgan Stanley
New York
|
+$10.8M |
| 3 |
ABG
Ally Bridge Group
New York
|
+$9.34M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$9.31M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$7.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.94M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.37M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$4.99M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$1.09M |
| 5 |
BP
BBR Partners
New York
|
-$1.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QCG
126
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$695 | -27 | Closed |
|
127
AssetMark Inc
Concord,
California
| – | -$540 | -21 | Closed |
|
|
CCM
128
Coldstream Capital Management
Bellevue,
Washington
| – | -$412 | -16 | Closed |
|
|
SAM
129
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$282 | -11 | Closed |
|
|
FFO
130
Fortitude Family Office
Scottsdale,
Arizona
| – | -$231 | -9 | Closed |
|
LENZ Hedge Fund Activity: Q2 2025 in Review
113 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2025, worth a combined $725M — up 34% from $542M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LENZ positions and 16 closed out — a net gain of 8 holders — while 53 added to existing stakes and 15 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $15.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.94M.
- 113 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2025, up from 105 in Q1 2025.
- Funds reported $725M of LENZ Therapeutics stock for Q2 2025, up 34% quarter-over-quarter.
- 24 funds opened new LENZ Therapeutics positions in Q2 2025 and 16 closed out, a net change of +8 holders.
- The largest LENZ Therapeutics buyer in Q2 2025 was Adage Capital Partners, an estimated $15.9M added.
- The largest LENZ Therapeutics seller in Q2 2025 was T. Rowe Price Associates, an estimated $7.94M sold.
Based on aggregated 13F filings for Q2 2025.